Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
05 sept. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the enrollment of the last subject in the Phase 1b study evaluating ARQ-255 for the treatment of alopecia areata.
Alopecia Areata Market Size Expected to Reach USD 6.30 Bn by 2032
22 mai 2024 11h17 HE
|
Precedence Research
Ottawa, May 22, 2024 (GLOBE NEWSWIRE) -- The global alopecia areata market size was valued at USD 3.09 billion in 2023 and is predicted to hit around USD 5.68 billion by 2031, a study published by...
Eli Lilly's Olumiant and Pfizer's Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain
15 nov. 2023 11h22 HE
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Spherix Global Insights has been monitoring the alopecia areata (AA) market for the past four years and has found that the entry of JAK...
NAAF’s Inaugural Walk For Alopecia Scheduled for September 30, 2023
30 août 2023 12h26 HE
|
National Alopecia Areata Foundation
San Rafael, CA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- For anyone living with or touched by alopecia areata, you do not have to walk alone! The National Alopecia Areata Foundation is holding its first...
Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata
11 juil. 2023 09h58 HE
|
Spherix Global Insights
Exton, Pennsylvania, July 11, 2023 (GLOBE NEWSWIRE) -- In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia...
Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255
05 déc. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
ARQ-255 is a topical janus kinase (JAK) inhibitor therapy specifically designed as a potential treatment for alopecia areataProprietary Deep Dermal Drug Delivery (4D) formulation designed to deliver...
Throne Biotechnologies Wins '5 Best BioTech Companies To Watch' Award From The Silicon Review
28 mars 2022 09h00 HE
|
Throne Biotechnologies Inc
PARAMUS, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Throne Biotechnologies (Throne), one of the global-leading biotech companies aiming to find a cure for type 1 diabetes and other autoimmune...
Throne Biotechnologies Launches Equity Crowdfunding to Support Phase 2 Clinical Trials in Type 1 Diabetes and Alopecia Areata
28 févr. 2022 09h00 HE
|
Throne Biotechnologies Inc
PARAMUS, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Throne Biotechnologies, one of the global-leading biotech companies aiming to find a cure for type 1 diabetes, announced the launch of their...
Alopecia Areata Clinical Trials Report: Pipeline Insight 2021 by DelveInsight
23 mars 2021 20h30 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, March 23, 2021 (GLOBE NEWSWIRE) -- Alopecia Areata Clinical Trials Report: Pipeline Insight 2021 by DelveInsight The increasing R&D investments for strong Alopecia Areata...
Alopecia Market To Reach USD 12.99 Billion By 2026 | Reports And Data
25 avr. 2019 13h26 HE
|
Reports And Data
Rising incidences of chronic disorders such as hyperthyroidism, acute stress disorder hypopituitarism, hypothyroidism, and lupus are the major factors influencing market growth. Market Size – USD...